Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: diabetes therapeutics - Hyundai Pharmaceuticals

Next Previous
X
Search
Drug Profile

Research programme: diabetes therapeutics - Hyundai Pharmaceuticals

Alternative Names: HD-0472936; HD-2355; HD-2356; HD-2936; HOB-046

Latest Information Update: 28 Jul 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hyundai Pharmaceutical
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action 11-beta-hydroxysteroid dehydrogenase inhibitors; FFAR1 protein stimulants; GPR119 protein agonists; Peroxisome proliferator-activated receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 28 Jul 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in South Korea (PO)
  • 09 Jun 2017 Preclinical trials in Type-2 diabetes mellitus in South Korea (PO) before June 2017
  • 01 Mar 2015 Early research in Type-2 diabetes mellitus in South Korea (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top